Recently, we have seen selected TKIs demonstrating a benefit in early-stage NSCLCs, as seen in the ADAURA (osimertinib in adjuvant EGFRm NSCLC) and ALINA (alectinib in adjuvant ALK+ NSCLC) studies [5,6]. This evidence concerns the gene ALK and non-small cell lung carcinoma.